Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

DNA vaccines for the treatment of prostate cancer.

Alam S, McNeel DG.

Expert Rev Vaccines. 2010 Jul;9(7):731-45. doi: 10.1586/erv.10.64. Review.

PMID:
20624047
2.

Tumor vaccines for the management of prostate cancer.

McNeel DG, Disis ML.

Arch Immunol Ther Exp (Warsz). 2000;48(2):85-93. Review.

PMID:
10807048
3.

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.

Arlen PM, Gulley JL, Tsang KY, Schlom J.

Expert Rev Vaccines. 2003 Aug;2(4):483-93. Review.

PMID:
14711334
4.

Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.

Hwang C, Sanda MG.

Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Review.

PMID:
11713762
5.

DNA vaccines for cancer.

Boyd D, Hung CF, Wu TC.

IDrugs. 2003 Dec;6(12):1155-64. Review.

PMID:
14666426
7.

Prostate cancer immunotherapy.

McNeel DG.

Curr Opin Urol. 2007 May;17(3):175-81. Review.

PMID:
17414515
8.

PSA-based vaccines for the treatment of prostate cancer.

Madan RA, Gulley JL, Arlen PM.

Expert Rev Vaccines. 2006 Apr;5(2):199-209. Review.

PMID:
16608420
9.

Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

J Clin Immunol. 2007 Jan;27(1):117-30.

PMID:
17180470
10.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
11.

Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG.

Vaccine. 2006 Jan 16;24(3):293-303.

PMID:
16115700
12.

Advances in specific immunotherapy for prostate cancer.

Kiessling A, F├╝ssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.

Eur Urol. 2008 Apr;53(4):694-708. Review.

PMID:
18061335
13.

DNA vaccines: an active immunization strategy for prostate cancer.

Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI.

Semin Oncol. 2003 Oct;30(5):659-66. Review.

PMID:
14571413
14.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Review.

PMID:
24332642
15.

Progress in active specific immunotherapy of prostate cancer.

Tjoa BA, Murphy GP.

Semin Surg Oncol. 2000 Jan-Feb;18(1):80-7. Review.

PMID:
10617899
16.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG.

Cancer Immunol Immunother. 2007 Jun;56(6):885-95.

PMID:
17102977
17.

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE.

Urology. 1999 Feb;53(2):260-6.

PMID:
9933036
18.

Vaccine therapy for prostate cancer.

Sonpavde G, Spencer DM, Slawin KM.

Urol Oncol. 2007 Nov-Dec;25(6):451-9. Review.

PMID:
18047951
19.

Current immunotherapeutic strategies in prostate cancer.

Grosso JF, Drake CG.

Surg Oncol Clin N Am. 2007 Oct;16(4):861-71, x. Review.

PMID:
18022549
20.

Immunotherapeutics in development for prostate cancer.

Harzstark AL, Small EJ.

Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Review.

Items per page

Supplemental Content

Support Center